ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0950

The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders

Ken Cai1, Billy Wu2, Nicola Dalbeth2, Rod Jackson2 and Katrina Poppe2, 1University of Auckland, Sydney, New South Wales, Australia, 2University of Auckland, Auckland, New Zealand

Meeting: ACR Convergence 2020

Keywords: Cardiovascular, gout, primary care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Metabolic & Crystal Arthropathies (0950–0954)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular disease (CVD). Individual-level cardiovascular risk prediction equations have been developed and validated for the New Zealand population using a comprehensive primary care dataset (PREDICT-1°) (Pylypchuk, Lancet 2018). We assessed the performance of these equations in people with gout and recalibrated the primary prevention equation to improve the prediction of CVD events in people with this condition.

Methods: The PREDICT study recruits people in primary care when general practitioners in New Zealand use PREDICT software to routinely assess their patients’ risk profile for CVD, which are prospectively linked to national ICD-coded hospitalisation and mortality databases. The study population included men and women (ages 30-74 years) who had no prior CVD, renal disease or congestive heart failure. A validated national health data definition of gout was used to identify those with gout: discharge diagnosis of gout (ICD-9 274, ICD-10 M10) from a public hospital admission or dispensed gout specific medications (Winnard, Rheumatology 2012). Baseline estimates of 5-year CVD risk (of cardiovascular death, non-fatal myocardial infarction, stroke, or other vascular event) were calculated using sex-specific PREDICT-1° risk scores and initially assessed via the slope between estimated and observed risk on the calibration plot (“slope”). Gout was added as a binary predictor to the recalibrated risk models.

Results: From January 1, 2007 to December 31, 2018, 441,723 people (56% men) had a PREDICT-1° risk assessment (Table). Of these, 23,229 met the definition of gout (3325 females and 19,904 males). In the whole cohort, 14,693 (3.3%) people had a first CVD event within 5 years of risk assessment. Of these, 1505 occurred in people with gout (6.5% event rate) and 13,188 occurred in people without gout (3.2% event rate). The risk scores underestimated the risk of CVD events in people with gout compared with people without gout (slope = 0.88) (Figure). This was more pronounced in women with gout (slope = 0.77) compared with men (slope = 0.96). Adding gout to the recalibrated risk estimates demonstrated that gout was independently associated with an increased risk of CVD events (adj. HR (95% CI) = 1.24 (1.08-1.42) for women; 1.21 (1.14-1.28) for men).

Conclusion: Current cardiovascular risk prediction equations underestimate the risk of CVD in people with gout. Despite adjustment for known CVD risk factors, gout independently increased the hazard ratio for CVD events.

Table. Participant characteristics (n = 441,723). Data are shown n (%), except age in years.

Figure. Estimated versus actual CVD event rate in people with and without gout.


Disclosure: K. Cai, None; B. Wu, None; N. Dalbeth, AstraZeneca, 1, 2, Abbvie, 1, Arthrosi, 1, Dyve BioSciences, 1, Selecta, 1, Janssen, 1; R. Jackson, None; K. Poppe, None.

To cite this abstract in AMA style:

Cai K, Wu B, Dalbeth N, Jackson R, Poppe K. The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-association-between-gout-and-cardiovascular-disease-outcomes-assessment-and-recalibration-of-individual-level-primary-prevention-risk-prediction-equations-in-approximately-450000-new-zealanders/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-gout-and-cardiovascular-disease-outcomes-assessment-and-recalibration-of-individual-level-primary-prevention-risk-prediction-equations-in-approximately-450000-new-zealanders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology